{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-300218","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.432573+00:00","generated_at":"2026-06-21T08:03:39.201699+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Syndax Pharmaceuticals prices $150M public offering of 6.8M shares at $22.00 per share","bullets":["6,818,182 shares offered at $22.00 each; underwriters have 30-day option for 1,022,727 additional shares.","Gross proceeds expected ~$150M ($172.5M if option fully exercised).","Underwriting led by Goldman Sachs, J.P. Morgan, and Cowen; closing expected December 9, 2022.","Directors, executive officers, and company subject to 60-day lock-up on share sales without consent.","Offering made under effective shelf registration statement (File No. 333-254661)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-300218","json":"https://secwatch.observer/filing/0001193125-22-300218.json","markdown":"https://secwatch.observer/filing/0001193125-22-300218.md","text":"https://secwatch.observer/filing/0001193125-22-300218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312522300218/0001193125-22-300218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312522300218/d420073d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:03:39.201699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b09c507602686d45408de84ca658c540ac26b44d","claim":"Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC valued at approximately $150.0 million (effective 2022-12-06).","evidence_excerpt":"On December 6, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 6,818,182 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $22.00 per share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312522300218/0001193125-22-300218-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC"},{"label":"Value","value":"approximately $150.0 million"},{"label":"Effective","value":"2022-12-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}